# Cyclacel Pharmaceuticals

Source: https://onco.cc/companies/cyclacel/  
OnCo record `cyclacel` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cyclacel is a cell-cycle drug company whose nucleoside analogue sapacitabine failed its phase 3 trial in older patients with acute myeloid leukaemia; it now develops CDK and PLK inhibitors.

## Summary

Cyclacel Pharmaceuticals, founded in 1997 with roots in Dundee and headquartered in Berkeley Heights, New Jersey, ran the phase 3 SEAMLESS trial of oral sapacitabine alternating with decitabine in elderly acute myeloid leukaemia, which did not meet its survival endpoint. It continues with the CDK2/9 inhibitor fadraciclib and a PLK1 inhibitor in early trials, registered on ClinicalTrials.gov under Cyclacel as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Cyclacel Pharmaceuticals, Inc.; Cyclacel
- Tags: ctgov-sponsor
- HQ: Berkeley Heights, NJ
- Type: biotech
- Website: http://www.cyclacel.com

## Sources

- Official website: http://www.cyclacel.com
- ClinicalTrials.gov: trials led by Cyclacel Pharmaceuticals, Inc.: https://clinicaltrials.gov/search?lead=Cyclacel%20Pharmaceuticals%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q5198104

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/cyclacel.json